| The use of FISH on breast core needle samples for the presurgical assessment of HER-2 oncogene status. | breast, |
| The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC). | lung, |
| Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. | breast, |
| CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast. | breast, |
| ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients. | breast, |
| Lack of ErbB-2 oncogene product overexpression in soft tissue sarcomas. | sarcoma, |
| Prognostic value of the quantitative measurement of the oncoprotein p185(Her-2/neu) in a group of patients with breast cancer and positive node involvement. | breast, |
| Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells. | breast, |
| Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. | bladder, |
| Prognostic and predictive value of HER2/neu oncogene in breast cancer. | breast, |
| Epithalon inhibits tumor growth and expression of HER-2/neu oncogene in breast tumors in transgenic mice characterized by accelerated aging. | breast, |
| Immunofluorescent localization of C-erbB-2 oncoprotein in breast cancer: a preliminary study. | breast, |
| Evaluation of the circulating fraction of the HER-2/neu oncogene in patients with cervical cancer. | cervical, |
| Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. | breast, |
| Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix. | uterine,breast, |
| Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. | breast, |
| [Loss of p53 gene and amplification of HER-2 oncogene in primary hepatocellular carcinoma and their clinical significance]. | liver, |
| HER-2/neu oncogene expression and DNA ploidy in normal human kidney and renal cell carcinoma. | kidney, |
| Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer. | breast, |
| HER-2/neu gene product in serum--an oncoprotein in the diagnosis and therapy of breast carcinoma. | breast, |